Cannon CP, de Lemos JA, Rosenson RS, et al. - This study was undertaken to present LDL-C treatment patterns in the US over 2 years. Researchers designed a prospective observational registry study (GOULD) involving multiple centers. Individuals were included in 1 of 3 cohorts: those currently receiving proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) and 2 groups not receiving PCSK9i drugs, with LDL-C levels of 100 mg/dL or more or LDL-C levels of 70 to 99 mg/dL between December 2016 and July 2018. The study enrolled a sum of 5,006 patients (mean [SD] age, 67.8 [9.9] years; 1985 women [39.7%]; 4,312 White individuals [86.1%]). Among individuals with ASCVD, most with suboptimal LDL-C levels at baseline, only 17.1% had LLT intensification after 2 years, and two-thirds remained at an LDL-C level greater than 70 mg/dL. There is a need for further intensive efforts to achieve optimal LDL-C management in patients with ASCVD.